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Autoimmune phenomena were identified in many different cases of hematological diseases and solid tumors,
which may be due to alterations in the expression and function of the NF-κB signaling pathway. Recently, a
number of studies have shown that the deletion or mutation of A20, a negative regulator of NF-κB, is frequently
found in lymphomas, suggesting that it may be a linker between the altered immune response and
leukemogenesis. The aim of this review is to summarize current findings of the A20 biological functions and its
molecular mechanism as a tumor suppressor and immune regulator. The identification of A20 mutations and
deletions in lymphocytic malignancy and the predictive significance of these aberrations are also reviewed.
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Autoimmune phenomena were identified in many differ-
ent cases of hematological diseases and solid tumors in
which abnormal A20 expression was characterized.
Recently, a number of studies have shown that A20 dele-
tions and mutations are frequently found in lymphomas,
suggesting that it may be involved in pathogenesis [1].
A20 is also known as tumor necrosis factor-α (TNFα)-
induced protein 3 (TNFAIP3), which was first discovered
in 1990 by Dixit and colleagues as a cytokine-induced
gene in human umbilical vein endothelial cells [2,3].
This protein was originally identified as a key regulator
of inflammation signaling pathways and a negative regu-
lator of the nuclear factor kappa B (NF-κB) activation
pathway, which could attenuate the NF-κB activity
triggered by signaling from several surface receptors
including tumor necrosis factors receptor (TNFR), Toll-
like receptor (TLR), and B cell receptor (BCR) [4].
The A20 structure and expression features
The A20 gene is located on chromosome 6q23.3, and
the cDNA sequence is 4,440 bp long with an open read-
ing frame of 2,370 nucleotides that encodes a protein* Correspondence: yangqiuli@hotmail.com
1Institute of Hematology, Medical College, Jinan University, Guangzhou
510632, China
3Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan
University, Guangzhou 510632, China
Full list of author information is available at the end of the article
© 2012 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpredicted to contain 790 amino acids. A20 contains
seven zinc finger (ZnF) domains in its C-terminus in-
cluding one that functions as an E3 ligase, while an
OUT (ovarian tumor) domain is embedded in its N-
terminus [2,3,5-9]. Structural studies have revealed that
the fourth zinc finger (ZnF4) interacts with mono-
ubiquitins and K63-linked polyubiquitin chains [9].
A20 expression may be induced in multiple organs by
various stimuli including interleukin-1β(IL-1β), TNF-α,
and Epstein-Barr virus (EBV) - latent membrane pro-
tein1(LMP1). Although A20 is inducible by proinflam-
matory cytokines in most cell types, the regulation of
A20 differs in lymphocytes. Temporally restricted and
tissue-specific A20 expression patterns were observed
with strikingly high levels in lymphoid organs including
the thymus, spleen, and gut-associated lymphoid tissue.
A20 is constitutively expressed in immature and mature
thymocyte subpopulations and resting peripheral T cells.
T cell activation leads to the down-regulation of A20
expression in mature thymocytes and peripheral T cells.
TNF does not induce A20 expression in activated T cells
even though these cells express TNF receptors. Thus,
although A20 has been frequently described as an indu-
cible immediate early gene in T cells, constitutive A20
expression is the prevailing pattern in these cells. Inter-
estingly, constitutive A20 expression is not found in rest-
ing B cells, indicating the differential regulation of this
gene among the B and T lineages [4,10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A20 has been reported to be a ubiquitin-editing enzyme
with several functions. Although A20 was initially
described as an inhibitor of TNF-induced cell death [11],
subsequent studies demonstrated that A20 overexpres-
sion inhibited NF-κB activation in response to different
stimuli [12,13]. Stable overexpression of A20 in a number
of cell lines, such as the human breast carcinoma MCF7
cells and murine fibrosarcoma WEHI164 cells, was
shown to result in partial resistance to TNF-induced
apoptosis. It should be noted that inhibition of A20-
mediated apoptosis has not been observed in all cell lines
studied. For example, A20 overexpression in the human
cervical carcinoma HeLa, lung epithelial A549, or human
hepatoma HepG2 cells had no effect on apoptosis
induced by the Fas receptor, lymphokine-activated killer
cells, serum depletion, or oxidative stress [10]. The rea-
son why some cell lines are protected by A20 and others
are not is still unclear. However, recent studies have indi-
cated that the most important A20 function is its func-
tion as a crucial tumor suppressor, and its deletion is
closely associated with lymphomas [6].
NF-κB inhibitory factor
The cloning and characterization of the A20 promoter
revealed two NF-κB DNA binding elements, which are
recognition sequences for NF-κB transcription factors. It
was also found that multiple NF-κB activating stimuli in-
duce A20 expression via NF-κB sites in the A20 promoter
[14]. Therefore, A20 has been demonstrated to downregu-
late its own expression, and it has been proposed that A20
participates in a negative feedback loop to attenuate
TNFα-induced inflammatory responses. Subsequent stud-
ies have demonstrated that A20 is also induced in many
other cell types by a wide variety of other stimuli including
activation of the B cell surface receptor CD40 and overex-
pression of HTLV-I Tax and EBV-LMP1 [15-19]. A20
overexpression was subsequently demonstrated to block
the NF-κB activation mediated by TNF, IL-1, lipopolysac-
charide (LPS), phorbol esters, and hydrogen peroxide in
different cell types [12,13,20-23]. This blockage is most
likely due to the inhibition of NF-κB activation in endo-
thelial cells in response to proinflammatory stimuli and to
an antiproliferative effect on smooth muscle cells as has
been observed upon A20 overexpression in vitro. All of
these findings suggest that A20 attenuates the activity of
proximal signaling complexes at pro-inflammatory recep-
tors [6,10]. The regulation of NF-‐κB signaling as it relates
to A20-mediated ubiquitylation in T cells is diagramed in
Figure 1 [6,24-27].
Regulation in innate and adaptive immunity
A20 regulates innate and adaptive immunity. This pro-
tein plays a pivotal role in the regulation of the immuneresponse and prevents excessive NF-κB activation in re-
sponse to a variety of external stimuli [28]. A20 has re-
cently been suggested to suppress T cell activation. A20
regulates the strength and duration of the IκB kinase
(IKK)/NF-κB response upon TCR/CD28 costimulation.
By catalyzing the removal of K63-linked ubiquitin chains
from mucosa associated lymphoid tissue 1 (MALT1),
A20 prevents a sustained interaction between ubiquiti-
nated MALT1 and the IKK complex, thus serving as a
negative regulator of inducible IKK activity. Upon T cell
stimulation, A20 is rapidly removed, and the paracaspase
activity of MALT1, which is known to be recruited to
lipid rafts after TCR stimulation, has been suggested to
cleave A20 [29].
A20 loss in B cells lowers their activation threshold
and enhances their proliferation and survival in a gene
dose-dependent fashion. Through the expression of
proinflammatory cytokines, most notably IL-6, A20-
deficient B cells trigger a progressive inflammatory reac-
tion in naïve mice, which is characterized by the expan-
sion of myeloid cells and effector-type T and regulatory
T cells [30].
Moreover, A20 also serve as a negative regulator of the
Toll-like receptor, which was found to play a crucial role
in controlling the maturation, cytokine production and
immunostimulatory potency of dendritic cells (DCs).
A20-silenced DCs demonstrated spontaneous and
enhanced expression of costimulatory molecules and
proinflammatory cytokines and had different effects on T
cell subsets i.e., they inhibited Treg cells and hyperacti-
vated tumor-infiltrating cytotoxic T and T helper cells,
which produce IL-6 and TNF-α, and were refractory to
Treg cell–mediated suppression. Hence, A20 serves as an
antigen presentation attenuator for the control of the
antitumor immune responses during the priming and ef-
fector phases and provides a strategy for overcoming
Treg cell–mediated suppression in an antigen-specific
manner, reducing the need for directly targeting Treg
cells [31].
Tumor suppressor
There are two different A20 expression patterns in
cancer cells. First, A20 overexpression was found in
undifferentiated nasopharyngeal carcinoma, poorly dif-
ferentiated head and neck squamous cell carcinomas
(SCCs) of the skin, estrogen receptor (ER)-negative
breast cancer cell lines, tamoxifen resistant ER-positive
tumors, and hepatitis B virus-related hepatocellular car-
cinoma [32]. Our recent study also found A20 overex-
pression in B-ALL samples that lack an A20 mutation
(unpublished), suggesting that A20 plays a role in the
pathogenesis of these malignancies. Moreover, A20 over-
expression has been associated with poor prognosis in ER
and progesterone receptor (PR)-negative breast tumor
Figure 1 Regulation of the NF-κB signaling related A20 protein by ubiquitylation in T cells.
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marker [6,10,27]. Second, and more importantly, A20
is inactivated in a substantial number of lymphomas
by deletion, promoter methylation, frameshift muta-
tions, and/or nonsense mutations that result in A20
truncations or point mutations. Notably, both A20
alleles are often affected, which is a hallmark of tumor
suppressor genes [6].
Increasing data support the notion that A20 is a tumor
suppressor. When re-expressed in a lymphoma-derived
cell line with no functional A20 alleles, wildtype but not
mutant A20 resulted in cell growth suppression and apop-
tosis induction accompanied by the downregulation of
NF-κB activation. In A20-deficient cells, the suppression
of cell growth and NF-κB activity due to A20 re-
expression depended, at least in part, on cell surface-
receptor signaling including that of the tumor necrosis
factor receptor. These findings indicate that uncontrolled
NF-κB signaling caused by the loss of A20 function is
involved in the pathogenesis of B cell lymphoma subsets,
and they strongly suggest a tumor suppressor role forA20, the loss of which may contribute to B cell lymphoma
pathogenesis by causing supra-physiological NF-κB activa-
tion, which, in turn, has oncogenic properties including
inhibiting apoptosis and promoting cell proliferation
[28,33].
Molecular mechanisms of the A20 biological functions
A20 functions as a ubiquitin-editing enzyme in the TNFR
pathway by first cleaving K63-linked polyubiquitin chains
on RIP1 (receptor interacting protein 1) followed by the
catalysis of K48-linked chains via ZnF4, which triggers
RIP1 proteasomal degradation [34]. In vitro studies con-
ducted with recombinant A20 have indicated that A20
does not efficiently hydrolyze K63-linked polyubiquitin
chains but instead has a preference for K48-linked polyu-
biquitin chains [35]. A20 cleaves Lys63-linked polyubiqui-
tin chains and promotes Lys48-linked polyubiquitin
chains, leading to negative regulation of TLR-mediated
NF-κB and/or IRF3 (interferon regulatory factor 3) activa-
tion by regulating their substrates including TRAF6
(TNFR-Associated Factor 6), TRAF3, and RIP1 [36].
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specificity for different pathways. One such protein is
TAX1BP1 (Tax1-binding protein 1), which is also known
as TXBP151. TAX1BP1 is a TRAF6-binding molecule that
negatively regulates TRAF6-induced NF-κB activation by
cooperating with the function of A20 and the E3 ubiquitin
ligase Itch, suggesting that it cooperates with A20 to in-
hibit cell death [37,38]. In addition, A20 associates with
TXBP151 through the A20 C-terminal zinc finger-
containing domain [10].
Regulation of A20 expression
A20 is regulated by the CARMA1–Bcl-10–MALT1
(CBM) upstream signaling pathway complex, which
bridges T cell antigen receptor (TCR) signaling with
the canonical IKK/NF-κB pathway (Figure 1) [6,24-
27]. TCR stimulation induced the recruitment of A20
and the Bcl-10 adaptor protein into the MALT1 com-
plex, leading to MALT1-mediated A20 processing.
Similarly, API2-MALT1 expression resulted in A20
cleavage. MALT1 cleaved human A20 at arginine 439
and impaired its NF-κB inhibitory function. Therefore,
A20 was identified as a MALT1 substrate, emphasiz-
ing the importance of MALT1 proteolytic activity in
‘fine tuning’ T cell antigen receptor signaling [29].
Moreover, microRNA dysfunction can contribute to
the constitutive activation of different signaling pathways
such as the NF-κB pathway. miR-125a and miR-125b
overexpression has been linked with dysfunctional
hematopoiesis and aberrant immune cell responses [39-
43]. miR-125a and miR-125b have been identified and
characterized as regulators of A20 expression and func-
tion and, consequently, NF-κB activity. The fine-tuning
of A20 levels mediated by miR-125 expression had a
striking impact on the K63-linked ubiquitination of
TRAF2 and RIP1, IκBα (inhibitor of nuclear factor kappa
B alpha) degradation, p65 nuclear accumulation, and
transcription of NF-κB target genes [44].
A20 gene alterations in lymphocytic malignancy
Recent studies have shown that A20 is frequently inacti-
vated by deletions and/or mutations in several lymph-
oma subtypes including marginal zone lymphoma
(MZL), diffuse large B-cell lymphoma (DLBCL), follicu-
lar lymphoma (FL), extranodal marginal zone lymphoma
(EMZL) of MALT, primary mediastinal B-cell lymph-
oma, and Hodgkin’s lymphoma (HL). A20 deficiency has
also been found in Sezary syndrome, which is a cutane-
ous T cell lymphoma, particularly those characterized by
constitutive NF-κB activation [1,28,33,45-47].
A20 deletion and mutation
There are numerous reports demonstrating different
A20 mutations and deletions in lymphocytic malignancy,and the most frequent A20 alteration was found in B cell
lymphoma; however, the frequency of A20 abnormalities
is relatively different in different reports, while the most
frequency of A20 mutations was found in B cell lymph-
oma. The various A20 alterations in lymphocytic malig-
nancies are summarized in Table 1. The most frequent
deletions or mutations involve exons 3, 6, and 7.
Promotor methylation
The methylation-mediated silencing of genes is an
epigenetic mechanism implicated in cancer. The CpG
island-associated A20 promoter was previously found
in osteosarcoma cells [56]. Thus, promoter methyla-
tion is another A20 inactivation mechanism. A study
by Chanudet E et al. demonstrated that A20 promoter
methylation was observed in 26% (7/27) of MALT
lymphoma cases including five ocular adnexal and
two extra-ocular cases. Of these seven cases, six
demonstrated a similar methylation pattern with
prominent methylation at the 7th, 8th and 9th CpG
sites. These findings are in line with the expected role
of promoter methylation in the transcriptional silen-
cing of the remaining A20 allele [50].
The role of A20 in the pathogenesis of lymphocytic
malignancy
The association between A20 dysfunction and lymphocytic
malignancy
Recent genome-wide association studies have demon-
strated a strong link between A20 polymorphisms and
a collection of chronic inflammatory disorders includ-
ing autoimmune diseases [5]. The phenotype of mice
with full or conditional A20 deletion illustrates that
A20 expression is essential for preventing chronic in-
flammation and autoimmune pathology. In addition,
polymorphisms within the A20 genomic locus have
been associated with multiple inflammatory and auto-
immune disorders including systemic lupus erythemato-
sus (SLE), rheumatoid arthritis (RA), Crohn’s disease and
psoriasis [57]. Both SLE and RA are associated with a
significantly increased risk of lymphoma, particularly
MALT lymphoma. Moreover, MALT lymphomas of
the thyroid and salivary glands also frequently arise in
a background of an autoimmune disorder, and tumor
cells may be directly involved in the autoimmune
process [1]. These data imply that such a nonresol-
ving inflammation, which lacks A20, is a critical com-
ponent of cancer development.
The role of A20 inactivation in lymphocytic malignancy
The development of hematological malignancies is a
multistep process that requires at least two genetic
abnormalities for disease development. Increasing data
regarding the role of gene alterations such as that for
Table 1 A20 abnormalities in lymphocytic malignancy
Diagnosis Number of cases Deletion (%) Mutation (%) Location Reference
cHL 36 44 OUT, ZF domain [47]
EBV+ 16 12.5 -
EBV- 20 70 -
NSHL 15 33.3 Exons 3, 4, and 7 [28]
other HL 27 26 [48]
MZL 32 2 19 Exons 3, 6, and 7 [46]
EMZL 11 18 Exons 3 and 7
NMZL 9 33 Exons 3, 6, and 7
sMZL 12 8 Exon 6
sMZL 46 6.5 6.5 - [49]
MALTL 30 6 17.6 C1777T; C811T; G460T/△CT1877-8 [50]
87 21.8 Exons 3, 5, 6, 7, and 9 [28]
64 17.2 - [45]
9 11 Exon 3 [1]
DLBCL 64 7.8 2 [28]
102 38 - [45]
GCB type 18 22.2 - [45]
ABC type 28 50 - [45]
GCB type 44 2.3 - [33]
ABC type 37 32 23 - [33]
non-GC/NC-DCBCL 20 34 22 - [33]
MCL 35 0 - [28]
29 31 - [45]
FL 52 1.9 - [28]
23 26 - [45]
PMBL 14 36 - [47]
Burkitt L 19 10.5 - [45]
NK L 27 18.5 - [45]
ATLL 68 10.3 - [45]
PTCL-u 51 9.8 - [45]
CTCL 13 46 - [51]
ARL 33/19 18 16 - [52]
PCNSL 32 3 - [53]
spinal cord DLBCL 10 10 - [53]
CLL 48 27 2 - [54,55]
55 0
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EKLF for acute myeloid leukemia, STAT3 for non-
GCB DLBCL, and PPP2R5C and BCL11B for T-ALL
were described, and some of these genes were
thought to be correlated with leukemogenesis, poor
overall survival or as a prognostic or therapeutic tar-
get factor [58-62]. The novel data demonstrating the
significant contribution of A20 inactivation resulting
in the constitutive activation of the NF-κB pathway isconsidered to be associated with cancer pathogenesis;
at a minimum, it plays a crucial role in the carcino-
genesis of certain lymphoid malignancies. It is now
clear that the genetic loss of A20 may predispose to
certain lymphoid malignancies [34]. CLL with unmu-
tated IGHV genes that demonstrate poorer survival
mostly have an A20 deletion. In this case, A20 may
be a biomarker and a potential target for the under-
lying mechanism and treatment of CLL [55].
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A20 acts as a negative feedback regulator of NF-κB acti-
vation in response to multiple stimuli and is considered
a tumor suppressor. A20 dysfunction may be related to
lymphocytic malignancy, and the exact A20 roles and
mechanisms in the pathogenesis of lymphocytic malig-
nancy, particularly in those with autoimmune disorders,
require further characterization. Moreover, evidence has
been presented suggesting that A20 and A20-binding
proteins may be used as biomarkers and potential novel
therapeutic targets in lymphocytic malignancies.
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